Back to search
High Risk Hematologic Malignancy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which High Risk Hematologic Malignancy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which High Risk Hematologic Malignancy trials you may qualify forThe purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatmen…
Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monito…
The drug that will be investigated in the trial is an antibody, GEN3018. Since this is the first trial of GEN3018 in humans, the main purpose is to evaluate saf…
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia t…
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undeterm…
Utilization data will be collected from all patients entered on the trial at Canadian centres from the time of registration until death, removal from study, or…
This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patient…
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).